NEW YORK, Oct. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
US Therapeutic Apheresis Industry
http://www.reportlinker.com/p0315732/US-Therapeutic-Apheresis-Industry.html
This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 18 companies including many key and niche players such as CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, Hospital Clinical Services Group, Inc., and Therakos, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
THERAPEUTIC APHERESIS MCP-1237
A US MARKET REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
A Peek into the Above-Mentioned Procedures 4
Plasmapheresis 4
Immunoadsorption 4
Erythrocytapheresis 4
Plateletpheresis 4
Leukapheresis 4
Photopheresis 5
Lipidpheresis 5
2. MARKET ANALYSIS 6
A Current & Future Analysis 6
A Promising Outlook 6
3. MARKET TRENDS 8
Apheresis Process Leads to Rise in Platelet Donors 8
Therapeutic Apheresis Devices - A Perplexing Market 8
Plateletpheresis: The Treatment of Choice for Patients 8
Photopheresis Market Growing at a High Rate 9
Vendors' Attitude Hampers Growth Prospects of Therapeutic
Apheresis 9
Developing New Applications for Therapeutic Apheresis is the
Need of the Hour 10
CFA - An Effective Way to Pull Up Cold Hemagglutinin Disease 10
4. COMPETITIVE SCENARIO 11
Overview 11
Technology: The Only Key for Success 11
CaridianBCT: The World Leader 11
Market Share Trends - A Historic Review 12
By Procedures (Revenues) 12
Table 1: US Market for Therapeutic Apheresis (2002 & 2005):
Percentage Breakdown of Revenues by Company for Gambro BCT,
Therakos, Fresenius Hemocare, Kaneka Pharma America
Corporation, Baxter Transfusion Therapies, and Others
(includes corresponding Graph/Chart) 12
By Procedures (Number of Procedures) 13
Table 2: US Market for Therapeutic Apheresis (2002 & 2005):
Percentage Breakdown of Number of Procedures by Company for
Gambro BCT, Therakos, Fresenius HemoCare, Haemonetics,
Baxter Transfusion Therapies, and Others (includes
corresponding Graph/Chart) 13
By Neurology Disorders (Revenues) 14
Table 3: US Market for Therapeutic Apheresis in Neurological
Disorders (2002 & 2005): Percentage Breakdown of Revenues by
Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and
Others (includes corresponding Graph/Chart) 14
By Neurology Disorders (Number of Procedures) 15
Table 4: US Market for Therapeutic Apheresis in Neurological
Disorders (2002 & 2005): Percentage Breakdown of Number of
Procedures by Company for Gambro BCT, Fresenius HemoCare,
Haemonetics, and Others (includes corresponding Graph/Chart) 15
By Hematology and Oncology Disorders (Revenues) 16
Table 5: US Market for Therapeutic Apheresis in Hematology
and Oncology Disorders (2002 & 2005): Percentage Breakdown
of Revenues by Company for Gambro BCT, Therakos, Fresenius
HemoCare, Baxter Transfusion Therapies, and Others (includes
corresponding Graph/Chart) 16
By Hematology and Oncology (Number of Procedures) 17
Table 6: US Market for Therapeutic Apheresis in Hematology
and Oncology Disorders in (2002 & 2005): Percentage
Breakdown of Number of Procedures by Company for Gambro BCT,
Fresenius HemoCare, Baxter Transfusion Therapies, Therakos,
and Others (includes corresponding Graph/Chart) 17
5. MARKET OVERVIEW & OUTLOOK 18
Market Drivers 18
New Reimbursement Policies Create Growth Opportunities for
Therapeutic Apheresis 18
Increased Industry Consolidation Drives Research 19
Development of New Technology 19
Research Unveils Novel Applications 19
Market Restraints 19
Lack of Awareness Restrains Growth 19
Therapeutic Apheresis Costs Still a Concern 19
Market Challenges 20
Development of Inexpensive Apheresis Therapy 20
Scarcity of Qualified Donors 20
Pediatry: An Untapped Opportunity 20
6. REGULATORY ENVIRONMENT 21
7. PRODUCT OVERVIEW 22
Therapeutic Apheresis: An Introduction 22
Overview of Therapeutic Apheresis 22
Blood Components 22
Apheresis and Therapeutic Apheresis: The Difference 23
Therapeutic Apheresis Process 23
Duration, Frequency, and Efficiency of Therapeutic Apheresis 23
Segregation of Blood Components 23
Centrifugation 24
Filtration 24
History 24
Types of Therapeutic Apheresis Procedures 25
Plasmapheresis 25
Erythrocytapheresis 25
Plateletpheresis 25
Leukapheresis 25
Stem Cell Apheresis 25
Photopheresis 26
Lipidpheresis 26
Cytapheresis 26
Immunoadsorption 26
Rheopheresis 26
Therapeutic Apheresis is Remedial for Various Diseases 27
8. PRODUCT TRENDS AND ISSUES 28
Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP)
Replacement 28
Risks Associated with Therapeutic Apheresis 28
Categories of Indications for Therapeutic Apheresis 29
Plasma Exchange and Plasmapheresis: The Difference 29
Applications of Plasma Exchange 29
Chronic Diseases 30
Acute Self-Limited Disease 30
Emerging Applications 30
9. PRODUCT AND TECHNOLOGICAL DEVELOPMENTS 31
CaridianBCT Introduces Spectra Optia® System Mononuclear Cell
Collection Protocol 31
Golden Meditech Company to Launch Model 3000H Plasma Exchange
System 31
HemoCleanse to Develop Novel Plasmapheresis Device 31
Aethlon Develops a New Device to Remove HIV 32
Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases 32
Occulogix Offers Blood-Filtering Treatment for Macular
Degeneration 33
10. RECENT INDUSTRY ACTIVITY 34
Therakos Obtains FDA Approval for THERAKOSTM CELLEXTM
Photopheresis System 34
Biotest Acquires Talecris' Plasma Collection Unit 34
Kawasumi Laboratories to Take Over Sales Rights from Kuraray 34
Sheikh Khalifa Medical City Launches Therapeutic Apheresis
Program 34
Asahi Kasei Kuraray Medical to Open New Laboratory 35
Gambro Changes Name to CaridianBCT 35
Therakos Obtains CE Mark in Europe 35
Baxter Divests Transfusion Therapies Business 36
SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance 36
Rheologics Technologies Takes Over Cardiodyne Electronics 36
Biotest Obtains Business Unit of Nabi BioPharmaceuticals 36
Gambro BCT Receives FDA Clearance for Spectra Optia System 36
MedaSorb Receives Rights for Blood Processing 37
Fresenius Medical Care Takes Over Renal Care 37
Haemonetics Signs Acquisition Agreement with Arryx 37
Cerus Receives Rights for INTERCEPT Blood System 37
Blood Systems to Implement Gambro BCT 7-day platelets 37
11. STRATEGIC CORPORATE DEVELOPMENTS IN RECENT PAST 38
Renal Care Pockets Bay Area Mobile Apheresis Program 38
Haemonetics Pacts with FMCEA 38
PhereSys and ACGT Ink Consulting Services Pact 38
CHF Forges a Service Provider Pact with FMCEA 38
Otsuka America Inks a Pact with HemaCare 39
Gambro Acquires Ivex 39
Fresenius HemoCare Becomes a Part of Fresenius Kabi 39
Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter 39
Gambro Signs Agreement with The American Red Cross 39
Gambro Receives Contract from NBS 40
FMC-EA Inks Deal with Allina Hospitals 40
Gambro Starts a New Company, Navigant Biotechnologies 40
Gambro's Vista™ Receives Approval from FDA 40
Gambro's New Anticoagulant Solution Receives FDA Approval 40
Gambro BCT Receives FDA Clearance for New Filter Tubing Sets
Developed by Pall 41
Gambro Launches Trima Accel Automated Blood Collection System 41
Fresenius HemoCare Acquires PROSORBA® Column from Cypress
Bioscience 41
Gambro Buys the Assets of Sanguistech 41
Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp 42
Gambro Joins Forces with the Walter Reed Army Institute of
Research 42
Gambro Collaborates with Dendreon for Commercialization of
Therapeutic Vaccines 42
Gambro AB Enters into a Partnership with Sangart 42
WakeMed Awards a Contract to HemaCare's Subsidiary 43
HemaCare's Subsidiary Coral in Agreement with CMH 43
BioTransplant Inks an Exclusive Distribution Agreement with
Gambro BCT 43
Gambro BCT Receives US Patent for its Pathogen Inactivation
Technology 43
Gambro's Trima Receives Approval from The Japanese Red Cross
Society 44
Gambro BCT Test Launches the Vista™ Information System 44
12. FOCUS ON SELECT PLAYERS 45
CaridianBCT, Inc. 45
Fenwal, Inc. 45
Fresenius Medical Care North America (FMCNA) 45
Haemonetics Corp. 46
HemaCare Corp. 46
Hospital Clinical Services Group, Inc. (HCSG) 46
Therakos, Inc. 47
13. MARKET PERSPECTIVE 48
Table 7: US Recent Past, Current & Future Market Analysis for
Therapeutic Apheresis by Procedure - Plasmapheresis,
Immunoadsorption, Erythrocytapheresis, Plateletpheresis,
Leukapheresis, Photopheresis and Lipidpheresis Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2007through 2015(includes corresponding Graph/Chart) 48
Table 8: US Historic Review for Therapeutic Apheresis by
Procedure - Plasmapheresis, Immunoadsorption,
Erythrocytapheresis, Plateletpheresis, Leukapheresis,
Photopheresis and Lipidpheresis Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2001 through
2006 (includes corresponding Graph/Chart) 49
Table 9: US 10-Year Perspective for Therapeutic Apheresis by
Procedure - Percentage Breakdown of Revenues for
Plasmapheresis, Immunoadsorption, Erythrocytapheresis,
Plateletpheresis, Leukapheresis, Photopheresis and
Lipidpheresis Markets Independently Analyzed for 2005, 2010 &
2015 (includes corresponding Graph/Chart) 50
Table 10: US Recent Past, Current & Future Market Analysis for
Therapeutic Apheresis by End Use - Neurology Disorders,
Hematology and Oncology Disorders, Rheumatology Disorders and
Other Markets Independently Analyzed with Annual Revenues in
US$ Thousand for Years 2007 through 2010 (includes
corresponding Graph/Chart) 51
Table 11: US Historic Review for Therapeutic Apheresis by
Disorder Type - Neurology, Hematology and Oncology,
Rheumatology and Others Markets Independently Analyzed with
Annual Revenues in US$ Thousand for Years 2001 through 2006
(includes corresponding Graph/Chart) 52
Table 12: US 10-Year Perspective for Therapeutic Apheresis by
End Use - Percentage Breakdown of Revenues for Neurology
Disorders, Hematology and Oncology Disorders, Rheumatology
Disorders and Other Markets Independently Analyzed for 2005,
2010 & 2015 (includes corresponding Graph/Chart) 53
COMPETITIVE LANDSCAPE
Total Companies Profiled: 18 (including Divisions/Subsidiaries - 21)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 17
Europe 4
Germany 3
Rest of Europe 1
------------------------------------------
To order this report:
Therapy Industry: US Therapeutic Apheresis Industry
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article